{"nctId":"NCT00089895","briefTitle":"EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)","startDateStruct":{"date":"2004-11-01","type":"ACTUAL"},"conditions":["Myocardial Ischemia","Acute Coronary Syndrome"],"count":9406,"armGroups":[{"label":"Eptifibatide","type":"EXPERIMENTAL","interventionNames":["Drug: Eptifibatide (Integrilin)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Eptifibatide (Integrilin)","otherNames":["Integrilin","SCH 060936","SCH 60936"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing and able to give informed consent and comply with study procedures and follow-up through 1 year.\n* Plan to undergo an invasive strategy after receiving study drug for 12 to 96 hours.\n* Able to be randomized into the trial within 12 hours of having symptoms of acute coronary syndrome.\n* Experiencing symptoms of cardiac ischemia at rest (angina or anginal equivalent) with episode(s) lasting at least 10 minutes and have at least 2 of the following:\n\n  * 60 years of age or more\n  * Electrocardiogram changes (ECG)\n  * Elevated troponin (protein released in the blood stream in people suffering from acute coronary syndrome) or CK-MB levels\n* Or have all 3 of the following:\n\n  * Prior history of cardiovascular disease\n  * Elevated troponin or CK-MB levels\n  * 50-59 years of age\n\nExclusion Criteria:\n\n* pregnancy (known or suspected)\n* renal dialysis within 30 days prior to randomizing in study\n* other serious illnesses or any condition that the investigator feels would pose a significant hazard to the patient if the investigational therapy was to be initiated\n* Stroke (hemorrhagic stroke at any time or non-hemorrhagic stroke within previous 7 days), central nervous system damage (such as neoplasm, aneurysm, intracranial surgery), bleeding disorders (including gastrointestinal bleeding), or recent major surgery or major trauma.\n* History of certain hematologic problems following treatment with heparin or eptifibatide.\n* Therapy with certain related drugs within a short time before randomization into the trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of the Composite of Death/MI.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"12.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":66,"n":4686},"commonTop":[]}}}